Skip to content
1887

Access Microbiology open research platform logo Access Microbiology

Volume 7, Issue 6

Optimizing synthetic cystic fibrosis sputum media for growth of non-typeable Open Access

Abstract

Non-typeable (NTHi) is an early pathogen isolated from the lungs of children with cystic fibrosis (CF). However, its role in the progression of CF lung infection is poorly understood. Additionally, whether it forms biofilms in the lungs of people with CF is an open question. The development of synthetic CF sputum media (SCFM) has given key insights into the microbiology of later CF pathogens, and , through replicating the chemical composition of CF sputum. However, the growth of NTHi in these media has not previously been reported. We show that NTHi grows poorly in three variants of SCFM commonly used to induce -like growth of and (SCFM1, SCFM2 and SCFM3). The addition of NAD and haemin to SCFM1 and SCFM2 promoted the planktonic growth and biofilm formation of both laboratory and clinical NTHi isolates, and we were able to develop a modified variant of SCFM2 that allows culture of NTHis. We show that NTHi cannot be identified in an established model of CF infection, which uses SCFM and porcine bronchiolar tissue. This may in part be due to the presence of endogenous bacteria on the pig lung tissue, which outcompete NTHi, but the lack of selective agar to isolate NTHi from endogenous bacteria, and the fact that NTHi is an exclusively human pathogen, makes it hard to conclude that this is the case. Through spiking modified SCFM2 with filter-sterilized lung homogenate, biofilm growth of clinical NTHi isolates was enhanced. Our results highlight that there are crucial components present in the lung tissue, which NTHi require for growth, which are not present in any published variant of SCFM from the Palmer Endres and Konstan in JAMA (2022;137:191-1) lineage. Our results may inform future modifications to SCFM recipes to truly mimic the environment of CF lung sputum and thus, to facilitate the study of a wide range of CF pathogens.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): biofilms , cystic fibrosis , infection models , non-typeable Haemophilus influenzae and synthetic cystic fibrosis sputum media
Funding
This study was supported by the:
  • Biotechnology and Biological Sciences Research Council (Award BB/M01116X/1)
    • Principle Award Recipient: PhoebeDo Carmo Silva
© 2025 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/acmi/10.1099/acmi.0.000979.v3
2025-06-20
2025-07-10
Loading full text...

Full text loading...

/deliver/fulltext/acmi/7/6/acmi000979.v3.html?itemId=/content/journal/acmi/10.1099/acmi.0.000979.v3&mimeType=html&fmt=ahah

References

  1. Endres TM, Konstan MW. What is cystic fibrosis?. JAMA 2022; 327:191 [View Article] [PubMed]
     [Google Scholar]
  2. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168:918–951 [View Article] [PubMed]
     [Google Scholar]
  3. Cystic Fibrosis Trust UK cystic fibrosis registry 2020; 2021 https://www.cysticfibrosis.org.uk/sites/default/files/2021-12/CF_Annual%20Report%202020_V8.pdf
  4. Abman SH, Ogle JW, Harbeck RJ, Butler-Simon N, Hammond KB et al. Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening. J Pediatr 1991; 119:211–217 [View Article] [PubMed]
     [Google Scholar]
  5. Goetz DM, Savant AP. Review of CFTR modulators 2020. Pediatr Pulmonol 2021; 56:3595–3606 [View Article] [PubMed]
     [Google Scholar]
  6. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365:1663–1672 [View Article] [PubMed]
     [Google Scholar]
  7. Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 2019; 394:1940–1948 [View Article]
     [Google Scholar]
  8. Watts SC, Judd LM, Carzino R, Ranganathan S, Holt KE. Genomic diversity and antimicrobial resistance of haemophilus colonizing the airways of young children with cystic fibrosis. mSystems 2021; 6:e0017821 [View Article] [PubMed]
     [Google Scholar]
  9. Heltshe SL, Mayer-Hamblett N, Burns JL, Khan U, Baines A et al. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. Clin Infect Dis 2015; 60:703–712 [View Article] [PubMed]
     [Google Scholar]
  10. Bessonova L, Volkova N, Higgins M, Bengtsson L, Tian S et al. Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Thorax 2018; 73:731–740 [View Article] [PubMed]
     [Google Scholar]
  11. Ronan NJ, Einarsson GG, Twomey M, Mooney D, Mullane D et al. CORK Study in Cystic Fibrosis: Sustained Improvements in Ultra-Low-Dose Chest CT Scores After CFTR Modulation With Ivacaftor. Chest 2018; 153:395–403 [View Article] [PubMed]
     [Google Scholar]
  12. Bilton D, Pye A, Johnson MM, Mitchell JL, Dodd M et al. The isolation and characterization of non-typeable Haemophilus influenzae from the sputum of adult cystic fibrosis patients. Eur Respir J 1995; 8:948–953 [PubMed]
     [Google Scholar]
  13. Rayner RJ, Hiller EJ, Ispahani P, Baker M. Haemophilus infection in cystic fibrosis. Arch Dis Child 1990; 65:255–258 [View Article] [PubMed]
     [Google Scholar]
  14. Bhatt JM. Treatment of pulmonary exacerbations in cystic fibrosis. Eur Respir Rev 2013; 22:205–216 [View Article] [PubMed]
     [Google Scholar]
  15. Möller LV, Timens W, van der Bij W, Kooi K, de Wever B et al. Haemophilus influenzae in lung explants of patients with end-stage pulmonary disease. Am J Respir Crit Care Med 1998; 157:950–956 [View Article] [PubMed]
     [Google Scholar]
  16. King P. Haemophilus influenzae and the lung (Haemophilus and the lung). Clin Transl Med 2012; 1:1–9 [View Article] [PubMed]
     [Google Scholar]
  17. Erwin AL, Smith AL. Nontypeable Haemophilus influenzae: understanding virulence and commensal behavior. Trends Microbiol 2007; 15:355–362 [View Article] [PubMed]
     [Google Scholar]
  18. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000; 13:302–317 [View Article] [PubMed]
     [Google Scholar]
  19. Oliver SE, Rubis AB, Soeters HM, Reingold A, Barnes M et al. Epidemiology of invasive nontypeable Haemophilus influenzae disease—United States, 2008–2019. Clin Infect Dis 2023; 76:1889–1895 [View Article] [PubMed]
     [Google Scholar]
  20. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284:1318–1322 [View Article] [PubMed]
     [Google Scholar]
  21. Høiby N. Understanding bacterial biofilms in patients with cystic fibrosis: current and innovative approaches to potential therapies. J Cyst Fibros 2002; 1:249–254 [View Article] [PubMed]
     [Google Scholar]
  22. Fux CA, Costerton JW, Stewart PS, Stoodley P. Survival strategies of infectious biofilms. Trends Microbiol 2005; 13:34–40 [View Article] [PubMed]
     [Google Scholar]
  23. Swords WE. Nontypeable Haemophilus influenzae biofilms: role in chronic airway infections. Front Cell Infect Microbiol 2012; 2:97 [View Article] [PubMed]
     [Google Scholar]
  24. Haley CL, Colmer-Hamood JA, Hamood AN. Characterization of biofilm-like structures formed by Pseudomonas aeruginosa in a synthetic mucus medium. BMC Microbiol 2012; 12:1–20 [View Article] [PubMed]
     [Google Scholar]
  25. Ferguson DL, Gloag ES, Parsek MR, Wozniak DJ. Extracellular DNA enhances biofilm integrity and mechanical properties of mucoid Pseudomonas aeruginosa. J Bacteriol 2023; 205:e0023823 [View Article] [PubMed]
     [Google Scholar]
  26. Yoon SS, Hennigan RF, Hilliard GM, Ochsner UA, Parvatiyar K et al. Pseudomonas aeruginosa anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis. Dev Cell 2002; 3:593–603 [View Article] [PubMed]
     [Google Scholar]
  27. Schaible B, Taylor CT, Schaffer K. Hypoxia increases antibiotic resistance in Pseudomonas aeruginosa through altering the composition of multidrug efflux pumps. Antimicrob Agents Chemother 2012; 56:2114–2118 [View Article]
     [Google Scholar]
  28. Moxon ER, Sweetman WA, Deadman ME, Ferguson DJP, Hood DW. Haemophilus influenzae biofilms: hypothesis or fact?. Trends Microbiol 2008; 16:95–100 [View Article] [PubMed]
     [Google Scholar]
  29. Dohar JE. Evidence that otitis media is not a biofilm disease. Ear Nose Throat J 2007; 86:8–12 [View Article]
     [Google Scholar]
  30. Langereis JD, Hermans PWM. Novel concepts in nontypeable Haemophilus influenzae biofilm formation. FEMS Microbiol Lett 2013; 346:81–89 [View Article] [PubMed]
     [Google Scholar]
  31. Ng J, Kidd SP. The concentration of intracellular nickel in Haemophilus influenzae is linked to its surface properties and cell-cell aggregation and biofilm formation. Int J Med Microbiol 2013; 303:150–157 [View Article] [PubMed]
     [Google Scholar]
  32. Gallaher TK, Wu S, Webster P, Aguilera R. Identification of biofilm proteins in non-typeable Haemophilus Influenzae. BMC Microbiol 2006; 6:1–9 [View Article] [PubMed]
     [Google Scholar]
  33. Weeks JR, Staples KJ, Spalluto CM, Watson A, Wilkinson TMA. The role of non-typeable Haemophilus influenzae biofilms in chronic obstructive pulmonary disease. Front Cell Infect Microbiol 2021; 11:720742 [View Article]
     [Google Scholar]
  34. Hong W, Juneau RA, Pang B, Swords WE. Survival of bacterial biofilms within neutrophil extracellular traps promotes nontypeable Haemophilus influenzae persistence in the chinchilla model for otitis media. J Innate Immun 2009; 1:215–224 [View Article] [PubMed]
     [Google Scholar]
  35. Post JC. Direct evidence of bacterial biofilms in otitis media. 2001. Laryngoscope 2015; 125:2003–2014 [View Article] [PubMed]
     [Google Scholar]
  36. Ehrlich GD, Veeh R, Wang X, Costerton JW, Hayes JD et al. Mucosal biofilm formation on middle-ear mucosa in the chinchilla model of otitis media. JAMA 2002; 287:1710–1715 [View Article] [PubMed]
     [Google Scholar]
  37. Hunt BC, Stanford D, Xu X, Li J, Gaggar A et al. Haemophilus influenzae persists in biofilm communities in a smoke-exposed ferret model of COPD. ERJ Open Res 2020; 6:00200-2020 [View Article] [PubMed]
     [Google Scholar]
  38. Starner TD, Zhang N, Kim G, Apicella MA, McCray PB Jr. Haemophilus influenzae forms biofilms on airway epithelia: implications in cystic fibrosis. Am J Respir Crit Care Med 2006; 174:213–220 [View Article] [PubMed]
     [Google Scholar]
  39. Palmer KL, Aye LM, Whiteley M. Nutritional cues control Pseudomonas aeruginosa multicellular behavior in cystic fibrosis sputum. J Bacteriol 2007; 189:8079–8087 [View Article] [PubMed]
     [Google Scholar]
  40. La Rosa R, Johansen HK, Molin S. Adapting to the airways: metabolic requirements of Pseudomonas aeruginosa during the infection of cystic fibrosis patients. Metabolites 2019; 9:234 [View Article] [PubMed]
     [Google Scholar]
  41. Harrington NE, Sweeney E, Alav I, Allen F, Moat J et al. Antibiotic efficacy testing in an ex vivo model of Pseudomonas aeruginosa and Staphylococcus aureus biofilms in the cystic fibrosis lung. J Vis Exp 2021e62187 [View Article] [PubMed]
     [Google Scholar]
  42. Harrington NE, Sweeney E, Harrison F. Building a better biofilm - formation of in vivo-like biofilm structures by Pseudomonas aeruginosa in a porcine model of cystic fibrosis lung infection. Biofilm 2020; 2:100024 [View Article] [PubMed]
     [Google Scholar]
  43. Sweeney E, Harrington NE, Harley Henriques AG, Hassan MM, Crealock-Ashurst B et al. An ex vivo cystic fibrosis model recapitulates key clinical aspects of chronic Staphylococcus aureus infection. Microbiology 2021; 167: [View Article]
     [Google Scholar]
  44. Aiyer A, Manos J. The use of artificial sputum media to enhance investigation and subsequent treatment of cystic fibrosis bacterial infections. Microorganisms 2022; 10:1269 [View Article] [PubMed]
     [Google Scholar]
  45. Peterson BW, van der Mei HC, Sjollema J, Busscher HJ, Sharma PK. A distinguishable role of eDNA in the viscoelastic relaxation of biofilms. mBio 2013; 4:e00497–13 [View Article] [PubMed]
     [Google Scholar]
  46. Lethem MI, James SL, Marriott C, Burke JF. The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum. Eur Respir J 1990; 3:19–23 [PubMed]
     [Google Scholar]
  47. Turner KH, Wessel AK, Palmer GC, Murray JL, Whiteley M. Essential genome of Pseudomonas aeruginosa in cystic fibrosis sputum. Proc Natl Acad Sci USA 2015; 112:4110–4115 [View Article] [PubMed]
     [Google Scholar]
  48. Neve RL, Carrillo BD, Phelan VV. Impact of artificial sputum medium formulation on Pseudomonas aeruginosa secondary metabolite production. J Bacteriol 2021; 203:e0025021 [View Article] [PubMed]
     [Google Scholar]
  49. Harrison F, Diggle SP. An ex vivo lung model to study bronchioles infected with Pseudomonas aeruginosa biofilms. Microbiology 2016; 162:1755–1760 [View Article] [PubMed]
     [Google Scholar]
  50. Sweeney E, Sabnis A, Edwards AM, Harrison F. Effect of host-mimicking medium and biofilm growth on the ability of colistin to kill Pseudomonas aeruginosa. Microbiology 2020; 166:1171–1180 [View Article] [PubMed]
     [Google Scholar]
  51. Cody AJ, Field D, Feil EJ, Stringer S, Deadman ME et al. High rates of recombination in otitis media isolates of non-typeable Haemophilus influenzae. Infect Genet Evol 2003; 3:57–66 [View Article] [PubMed]
     [Google Scholar]
  52. Mulay A, Akram KM, Williams D, Armes H, Russell C et al. An in vitro model of murine middle ear epithelium. Dis Model Mech 2016; 9:1405–1417 [View Article] [PubMed]
     [Google Scholar]
  53. Korten I, Kieninger E, Yammine S, Regamey N, Nyilas S et al. The swiss cystic fibrosis infant lung development (SCILD) cohort. Swiss Med Wkly 2018; 148:w14618–8 [View Article] [PubMed]
     [Google Scholar]
  54. Mostacci N, Wüthrich TM, Siegwald L, Kieser S, Steinberg R et al. Informed interpretation of metagenomic data by StrainPhlAn enables strain retention analyses of the upper airway microbiome. mSystems 2023; 8:e0072423 [View Article] [PubMed]
     [Google Scholar]
  55. Holloway BW. Genetic recombination in Pseudomonas aeruginosa. Microbiology 1955; 13:572–581 [View Article]
     [Google Scholar]
  56. Sprouffske K, Wagner A. Growthcurver: an R package for obtaining interpretable metrics from microbial growth curves. BMC Bioinf 2016; 17:172 [View Article] [PubMed]
     [Google Scholar]
  57. Harrison F, Muruli A, Higgins S, Diggle SP. Development of an ex vivo porcine lung model for studying growth, virulence, and signaling of Pseudomonas aeruginosa. Infect Immun 2014; 82:3312–3323 [View Article] [PubMed]
     [Google Scholar]
  58. Harrington NE, Littler JL, Harrison F. Transcriptome analysis of Pseudomonas aeruginosa biofilm infection in an ex vivo pig model of the cystic fibrosis lung. Appl Environ Microbiol 2022; 88:e0178921 [View Article] [PubMed]
     [Google Scholar]
  59. Glasser NR, Hunter RC, Liou TG, Newman DK, Investigators MWCC. Refinement of metabolite detection in cystic fibrosis sputum reveals heme correlates with lung function decline. PLoS One 2019; 14:e0226578 [View Article] [PubMed]
     [Google Scholar]
  60. Barben JU, Ditchfield M, Carlin JB, Robertson CF, Robinson PJ et al. Major haemoptysis in children with cystic fibrosis: a 20-year retrospective study. J Cyst Fibros 2003; 2:105–111 [View Article] [PubMed]
     [Google Scholar]
  61. Sagel SD, Kapsner R, Osberg I, Sontag MK, Accurso FJ. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med 2001; 164:1425–1431 [View Article] [PubMed]
     [Google Scholar]
  62. Lewis AL, Chen X, Schnaar RL, Varki A. Sialic acids and other nonulosonic acids. In Essentials of Glycobiology, 4th edition 2022
     [Google Scholar]
  63. Jackson MD, Wong SM, Akerley BJ. Sialic acid protects nontypeable Haemophilus influenzae from natural IgM and promotes survival in murine respiratory tract. Infect Immun 2021; 89:e00676-20 [View Article] [PubMed]
     [Google Scholar]
  64. Cantin AM, Bilodeau G, Larivée P, Richter MV. Plasma biomarkers and cystic fibrosis lung disease. Clin Invest Med 2012; 35:E173–81 [View Article] [PubMed]
     [Google Scholar]
  65. Román F, Cantón R, Pérez-Vázquez M, Baquero F, Campos J. Dynamics of long-term colonization of respiratory tract by Haemophilus influenzae in cystic fibrosis patients shows a marked increase in hypermutable strains. J Clin Microbiol 2004; 42:1450–1459 [View Article] [PubMed]
     [Google Scholar]
  66. Begum N, Byrnes CA, Cheney J, Cooper PJ, Fantino E et al. Factors in childhood associated with lung function decline to adolescence in cystic fibrosis. J Cyst Fibros 2022; 21:977–983 [View Article] [PubMed]
     [Google Scholar]
  67. Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999; 28:321–328 [View Article] [PubMed]
     [Google Scholar]
  68. Bjarnsholt T, Alhede M, Alhede M, Eickhardt-Sørensen SR, Moser C et al. The in vivo biofilm. Trends Microbiol 2013; 21:466–474 [View Article] [PubMed]
     [Google Scholar]
  69. Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 2004; 42:1915–1922 [View Article] [PubMed]
     [Google Scholar]
  70. Choong FX, Bäck M, Fahlén S, Johansson LB, Melican K et al. Real-time optotracing of curli and cellulose in live Salmonella biofilms using luminescent oligothiophenes. NPJ Biofilms Microbiomes 2016; 2:16024 [View Article] [PubMed]
     [Google Scholar]
  71. Dwyer M, Shan Q, D’Ortona S, Maurer R, Mitchell R et al. Cystic fibrosis sputum DNA has NETosis characteristics and neutrophil extracellular trap release is regulated by macrophage migration-inhibitory factor. J Innate Immun 2014; 6:765–779 [View Article] [PubMed]
     [Google Scholar]
  72. Fux CA, Shirtliff M, Stoodley P, Costerton JW. Can laboratory reference strains mirror “real-world” pathogenesis?. Trends Microbiol 2005; 13:58–63 [View Article] [PubMed]
     [Google Scholar]
  73. Moller LVM, Regelink AG, Grasselier H, Dankert-Roelse JE, Dankert J et al. Multiple Haemophilus influenzae strains and strain variants coexist in the respiratory tract of patients with cystic fibrosis. J Infect Dis 1995; 172:1388–1392 [View Article]
     [Google Scholar]
  74. Morey P, Cano V, Martí-Lliteras P, López-Gómez A, Regueiro V et al. Evidence for a non-replicative intracellular stage of nontypable Haemophilus influenzae in epithelial cells. Microbiology 2011; 157:234–250 [View Article]
     [Google Scholar]
  75. Cheema ZM, Gomez LC, Johnson N, Laflamme OD, Rabin HR et al. Measuring the burden of cystic fibrosis: a scoping review. J Cyst Fibros 2024; 23:823–830 [View Article] [PubMed]
     [Google Scholar]
  76. Ebbing R, Robertson CF. Haemophilus influenzae and Haemophilus parainfluenza in cystic fibrosis: 15 years experience. J Medical Microbiol Diagnosis 2015; s5:2161–0703 [View Article]
     [Google Scholar]
  77. Razvi S, Quittell L, Sewall A, Quinton H, Marshall B et al. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 2009; 136:1554–1560 [View Article] [PubMed]
     [Google Scholar]
  78. Abavisani M, Keikha M, Karbalaei M. First global report about the prevalence of multi-drug resistant Haemophilus influenzae: a systematic review and meta-analysis. BMC Infect Dis 2024; 24:90 [View Article] [PubMed]
     [Google Scholar]
  79. Garcia Maset R, Hapeshi A, Hall S, Dalgliesh RM, Harrison F et al. Evaluation of the antimicrobial activity in host-mimicking media and in vivo toxicity of antimicrobial polymers as functional mimics of AMPs. ACS Appl Mater Interfaces 2022; 14:32855–32868 [View Article] [PubMed]
     [Google Scholar]
  80. Barton TE, Frost F, Fothergill JL, Neill DR. Challenges and opportunities in the development of novel antimicrobial therapeutics for cystic fibrosis. J Med Microbiol 2022; 71: [View Article] [PubMed]
     [Google Scholar]
  81. Ersoy SC, Heithoff DM, Barnes L 5th, Tripp GK, House JK et al. Correcting a fundamental flaw in the paradigm for antimicrobial susceptibility testing. EBioMedicine 2017; 20:173–181 [View Article] [PubMed]
     [Google Scholar]
  82. Hammond A, Dertien J, Colmer-Hamood JA, Griswold JA, Hamood AN. Serum inhibits P. aeruginosa biofilm formation on plastic surfaces and intravenous catheters. J Surg Res 2010; 159:735–746 [View Article] [PubMed]
     [Google Scholar]
  83. Hernandez-Cuellar E, Guerrero-Barrera AL, Avelar-Gonzalez FJ, Díaz JM, Santiago AS de et al. Characterization of Candida albicans and Staphylococcus aureus polymicrobial biofilm on different surfaces. Rev Iberoam Micol 2022; 39:36–43 [View Article] [PubMed]
     [Google Scholar]
  84. Ardehali R, Shi L, Janatova J, Mohammad SF, Burns GL. The inhibitory activity of serum to prevent bacterial adhesion is mainly due to apo‐transferrin. J Biomedical Materials Res 2003; 66A:21–28 [View Article]
     [Google Scholar]
  85. Singh PK, Parsek MR, Greenberg EP, Welsh MJ. A component of innate immunity prevents bacterial biofilm development. Nature 2002; 417:552–555 [View Article] [PubMed]
     [Google Scholar]
  86. Domenech M, Pedrero-Vega E, Prieto A, García E. Evidence of the presence of nucleic acids and β-glucan in the matrix of non-typeable Haemophilus influenzae in vitro biofilms. Sci Rep 2016; 6:36424 [View Article] [PubMed]
     [Google Scholar]
  87. Jurcisek JA, Bakaletz LO. Biofilms formed by nontypeable Haemophilus influenzae in vivo contain both double-stranded DNA and type IV pilin protein. J Bacteriol 2007; 189:3868–3875 [View Article] [PubMed]
     [Google Scholar]
  88. Das J, Mokrzan E, Lakhani V, Rosas L, Jurcisek JA et al. Extracellular DNA and type IV pilus expression regulate the structure and kinetics of biofilm formation by nontypeable Haemophilus influenzae. mBio 2017; 8:10–1128 [View Article] [PubMed]
     [Google Scholar]
  89. Zafra O, Lamprecht-Grandío M, de Figueras CG, González-Pastor JE. Extracellular DNA release by undomesticated Bacillus subtilis is regulated by early competence. PLoS One 2012; 7:e48716 [View Article] [PubMed]
     [Google Scholar]
  90. Sharma DK, Rajpurohit YS. Multitasking functions of bacterial extracellular DNA in biofilms. J Bacteriol 2024; 206:e0000624 [View Article] [PubMed]
     [Google Scholar]
  91. Boboltz A, Yang S, Duncan GA. Engineering in vitro models of cystic fibrosis lung disease using neutrophil extracellular trap inspired biomaterials. J Mater Chem B 2023; 11:9419–9430 [View Article] [PubMed]
     [Google Scholar]
  92. Apicella MA. Nontypeable Haemophilus influenzae: the role of N-acetyl-5-neuraminic acid in biology. Front Cell Infect Microbiol 2012; 2:19 [View Article] [PubMed]
     [Google Scholar]
  93. Greiner LL, Watanabe H, Phillips NJ, Shao J, Morgan A et al. Nontypeable Haemophilus influenzae strain 2019 produces a biofilm containing N-acetylneuraminic acid that may mimic sialylated O-linked glycans. Infect Immun 2004; 72:4249–4260 [View Article] [PubMed]
     [Google Scholar]
  94. Swords WE, Moore ML, Godzicki L, Bukofzer G, Mitten MJ et al. Sialylation of lipooligosaccharides promotes biofilm formation by nontypeable Haemophilus influenzae. Infect Immun 2004; 72:106–113 [View Article] [PubMed]
     [Google Scholar]
  95. Hong W, Mason K, Jurcisek J, Novotny L, Bakaletz LO et al. Phosphorylcholine decreases early inflammation and promotes the establishment of stable biofilm communities of nontypeable Haemophilus influenzae strain 86-028NP in a chinchilla model of otitis media. Infect Immun 2007; 75:958–965 [View Article] [PubMed]
     [Google Scholar]
  96. Jurcisek J, Greiner L, Watanabe H, Zaleski A, Apicella MA et al. Role of sialic acid and complex carbohydrate biosynthesis in biofilm formation by nontypeable Haemophilus influenzae in the chinchilla middle ear. Infect Immun 2005; 73:3210–3218 [View Article] [PubMed]
     [Google Scholar]
  97. Cardines R, Giufrè M, Pompilio A, Fiscarelli E, Ricciotti G et al. Haemophilus influenzae in children with cystic fibrosis: antimicrobial susceptibility, molecular epidemiology, distribution of adhesins and biofilm formation. Int J Med Microbiol 2012; 302:45–52 [View Article] [PubMed]
     [Google Scholar]
  98. Dickerman A, Bandara AB, Inzana TJ. Phylogenomic analysis of Haemophilus parasuis and proposed reclassification to Glaesserella parasuis, gen. nov., comb. nov. Int J Syst Evol Microbiol 2020; 70:180–186 [View Article]
     [Google Scholar]
  99. Smith A, Baker M. Cefsulodin chocolate blood agar: a selective medium for the recovery of Haemophilus influenzae from the respiratory secretions of patients with cystic fibrosis. J Med Microbiol 1997; 46:883–885 [View Article] [PubMed]
     [Google Scholar]
  100. Chapin KC, Doern GV. Selective media for recovery of Haemophilus influenzae from specimens contaminated with upper respiratory tract microbial flora. J Clin Microbiol 1983; 17:1163–1165 [View Article] [PubMed]
     [Google Scholar]
  101. Kampf G, Lecke C, Cimbal AK, Weist K, Rüden H. Evaluation of mannitol salt agar for detection of oxacillin resistance in Staphylococcus aureus by disk diffusion and agar screening. J Clin Microbiol 1998; 36:2254–2257 [View Article] [PubMed]
     [Google Scholar]
  102. Sloane AJ, Lindner RA, Prasad SS, Sebastian LT, Pedersen SK et al. Proteomic analysis of sputum from adults and children with cystic fibrosis and from control subjects. Am J Respir Crit Care Med 2005; 172:1416–1426 [View Article] [PubMed]
     [Google Scholar]
/content/journal/acmi/10.1099/acmi.0.000979.v3
Loading
Optimizing synthetic cystic fibrosis sputum media for growth of non-typeable Haemophilus influenzae
Access Microbiology 7, 000979.v3 (2025); https://doi.org/10.1099/acmi.0.000979.v3
/content/journal/acmi/10.1099/acmi.0.000979.v3
/content/journal/acmi/10.1099/acmi.0.000979.v3
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Supplementary material 2

EXCEL

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error